Autoimmune disease, which affect millions worldwide, often require complex diagnostic processes that can delay treatment and adversely affect patient outcomes. The partnership between Pathkind and Sebia seeks to streamline this process, providing healthcare professionals with an efficient, user-friendly diagnostic tool that enhances patient care.

By integrating this cutting-edge technology into Pathkind’s network, Pathkind aims to make advanced autoimmune disease diagnostics more accessible and efficient.

Sebia’s Alegria system uses a monostrip format that simplifies the testing process while maintaining high accuracy and precision. This streamlined approach not only reduces the burden on laboratory resources but also empowers healthcare professionals to provide timely interventions.

“We are excited to expand our focus on autoimmunity testing through introduction of the Sebia’s Alegria Monotest technology, said Sanjeev Vashishta, Managing Director and CEO at Pathkind Diagnostics. This innovative system not only simplifies the diagnostic process but also significantly improves access to crucial testing for autoimmune diseases. By empowering healthcare professionals with this advanced technology, we are taking a significant step towards enhancing patient care and outcomes, particularly for those in underserved regions.”

Alegria® is a cutting-edge sample-to-result solution for autoimmunity that revolutionizes diagnostics for Rheumatology, Thrombosis, ANCA & Vasculitis, Gastroenterology, Thyroid, and Stool testing. Each Alegria® Monotest strip includes the complete set of reagents that are needed to perform the analysis for one individual patient result. Each test result is validated with its own integrated control for the highest reliability and quality in the lab.

With over 80 plus parameters in unique Alegria® Monotest portfolio, the Alegria® system offers unparalleled flexibility, allowing for customized biomarker profiles tailored to individual patient needs.

Post-COVID, India has seen a significant rise in autoimmune disorders, affecting millions of lives and creating an urgent need for advanced diagnostic solutions. These complex conditions often go undiagnosed or misdiagnosed, leading to delayed treatment and worsening patient outcomes. The introduction of Alegria Monotest technology aims to address this growing health crisis by offering precise, rapid, and reliable autoimmune testing, enabling earlier diagnosis and better patient care across the country.